Skip directly to search Skip directly to A to Z list Skip directly to the left nav Skip directly to the table data Skip directly to the reports section
Antibiotic resistance (AR), when germs do not respond to the drugs designed to kill them, threatens to return us to the time when simple infections were often fatal.

The AR Investment Map showcases the Centers for Disease Control & Prevention's (CDC) activities to meet national goals to prevent drug-resistant infections. CDC’s AR Solutions Initiative puts state and local AR laboratory and epidemiological expertise in every state and makes investments in public health innovation to fight AR across healthcare settings, food, and communities.

Local health department that received additional funding.
Location of one of seven AR Laboratory Network regional labs.
Location of the National Tuberculosis Molecular Surveillance Center.
Strategy PDF Preview

This map represents CDC’s largest funding categories for antibiotic resistance. It shows domestic, extramural funding that supports AR activities from multiple funding lines.

Investing to Defend the U.S. against Antibiotic Resistance
CDC is committed to protecting Americans and the future of healthcare, veterinary, and agriculture industries from the threat of antibiotic resistance. CDC supports most of these activities through its AR Solutions Initiative, while also leveraging investments from successful programs across the agency for maximum efficiency.

CDC partners with health departments, academia, and the healthcare, veterinary, and agriculture industries to grow the science and implement strategies that protect Americans from antibiotic resistance.

   Laboratory & Diagnostics: Gold-standard lab capacity offered to all state and regional labs through CDC’s AR Laboratory Network
   Epidemiology Capacity for Response: Increased capacity in state and local health departments for rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread

   Surveillance & Science: More effective prevention of healthcare-associated infections, foodborne illness, and gonorrhea
   Improved Antibiotic Use: With partners, improve antibiotic use to ensure antibiotics work to protect patients from life-threatening infections or sepsis

   Insights for Practice: With academic and healthcare partners, CDC is investing in innovations and collaborating with investigators to identify and implement new ways to prevent antibiotic-resistant infections and their spread
   Research and Development: Sharing isolates that inform development of new drugs and diagnostics, and making public CDC’s sequencing data from AR pathogens to spur innovation in industry

Get Email Updates

To receive email updates about this page, enter your email address:

What's this? Submit

Antibiotic Resistance Investments - Version